The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will wither -18.4% and EPS will wane 47.2%.
The average estimate for revenue is $105.1 million. On the bottom line, the average EPS estimate is $0.19.
Last quarter, ViroPharma reported revenue of $135.8 million. GAAP reported sales were 6.9% higher than the prior-year quarter's $127.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.25. GAAP EPS of $0.26 for Q1 were 35% lower than the prior-year quarter's $0.40 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.4%, 870 basis points worse than the prior-year quarter. Operating margin was 30.5%, 1,710 basis points worse than the prior-year quarter. Net margin was 14.7%, 1,400 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $448.9 million. The average EPS estimate is $0.92.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,205 members rating the stock outperform and 39 members rating it underperform. Among 295 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 286 give ViroPharma a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is hold, with an average price target of $33.07.
- Add ViroPharma to My Watchlist.